Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
-
New monthly HAE shot tested for safety after switching from current meds
Disease control OngoingThis study looks at whether it is safe for people aged 12 and older with hereditary angioedema (HAE) to switch from their current preventive medicine to a new monthly injection called garadacimab. Researchers will monitor for side effects over about 3 months. The goal is to see i…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New immune boost for rare immune disorder? small trial underway
Disease control OngoingThis study tests a drug called IgPro20, a type of immune globulin given under the skin, in adults with primary immunodeficiency who have never received such treatment. The goal is to see how the drug moves through the body and whether it is safe. Only 8 participants are enrolled,…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hemophilia a: experimental clotting factor shows promise in chinese trial
Disease control OngoingThis phase 3 trial is testing a new form of factor VIII (rVIII-SingleChain) in 60 Chinese men with severe hemophilia A. The goal is to see how well the drug works to prevent and treat bleeding episodes when given 2-3 times per week. Researchers will also check how the body proces…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New Long-Acting clotting drug could cut bleeding episodes in hemophilia b
Disease control OngoingThis phase 3 trial tests a long-acting clotting factor (rIX-FP) in 23 Chinese men with severe hemophilia B. The drug is given regularly to prevent bleeding episodes. Researchers will measure how well it works, how long it lasts in the body, and check for side effects like allergi…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC